In this article, we discuss 10 Stocks That Tanked: Why Larry Robbins’ Top Picks Are Struggling in 2026.

Larry Robbins is the founder, CEO, and portfolio manager of Glenview Capital Management, a New York-based hedge fund he launched in 2000. A protégé of Leon Cooperman at Omega Advisors, Robbins built Glenview into one of the industry’s most prominent Tiger Cub descendants, specifically known for a concentrated, research-intensive approach to growth-at-a-reasonable-price (GARP) investing. While Robbins is a diversified investor, he is most famously associated with the healthcare sector. His investment thesis often centers on predictable businesses, managed care providers, hospital chains, and pharmaceutical distributors, that he believes are undervalued by the broader market.

READ MORE: Billionaire Tom Steyer’s 10 Stock Picks with Huge Upside Potential and 10 Best Small-Cap Value Stocks to Buy According to Bares Capital.

His conviction is legendary. Robbins is known for maintaining massive positions even during periods of extreme volatility. This was most notable in 2015 when, after a period of significant underperformance, Robbins took the rare step of writing a candid letter to investors apologizing for the losses of the fund and declining his management fee for a period to realign his interests with his partners. While he generally avoids the hostile public theatrics of traditional corporate raiders, he frequently engages with management teams to suggest strategic shifts, such as spin-offs, share repurchases, or improved capital allocation.

Our Methodology

For this article, we selected stocks by combing through the 13F portfolio of Glenview Capital at the end of the fourth quarter of 2025. The stocks were ranked according to the year-to-date decline in share price and the top 10 from this list were filtered out. Data for the hedge fund sentiment surrounding each stock was taken from Insider Monkey’s Q4 2025 database of 1041 elite hedge funds.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).

Stocks That Tanked: Why Larry Robbins’ Top Picks Are Struggling in 2026

10. Global Payments Inc. (NYSE:GPN)

YTD Decline in Share Price: 10%

Glenview Capital’s Stake: $458 million

Global Payments Inc. (NYSE:GPN) has been a consistent feature in the 13F portfolio of Glenview Capital for the past several years. The fund first disclosed a stake in the company back in the third quarter of 2013. This position comprised just under 3 million shares. By the third quarter of 2014, the fund had grown this stake to over 4.5 million shares. Thereafter, it trimmed the holding and sold it off completely by the middle of 2015. A new position in the firm was opened in the fourth quarter of 2020. This consisted of over 60,000 shares. Filings for the fourth quarter of 2025 show that the fund owned 5.9 million shares in the company, up 15% compared to filings for the previous quarter.

Global Payments Inc. (NYSE:GPN) recently completed the purchase of Worldpay. In the May 6 earnings call, CEO Cameron Bready highlighted that the Worldpay integration was unlocking cross-sell opportunities that were previously inaccessible, specifically in the enterprise restaurant segment. Management expects at least $200 million in revenue synergies from these strategies. However, analysts contend that the firm is viewed by investors as a legacy incumbent that is being squeezed by more agile, tech-first rivals. As payment processing becomes increasingly commoditized, Global Payments may be forced to compete on price to retain its 6 million merchant locations, which could permanently compress its long-term margins despite current synergy targets.

9. Lithia Motors, Inc. (NYSE:LAD)

YTD Decline in Share Price: 14%

Glenview Capital’s Stake: $42 million

Lithia Motors, Inc. (NYSE:LAD) first featured in the 13F portfolio of Glenview Capital in the second quarter of 2014. This position comprised just under 850,000 shares. By the first quarter of 2015, the fund had grown this to around 1.4 million shares. Thereafter, it started trimming the shares and sold off this holding completely by early 2016. A new position in the firm was then disclosed in the third quarter of 2025. This holding comprised over 74,000 shares. Filings for the fourth quarter of 2025 show that the fund owned more than 127,000 shares in the company, up nearly 73% compared to filings for the previous quarter.

Lithia Motors, Inc. (NYSE:LAD) has continued to report record revenues, but hedge funds are increasingly concerned that the core business is being hollowed out by razor-thin margins and heavy debt. The most immediate concern is that the firm is operating on a margin of error that leaves it vulnerable to even minor economic shocks. The net profit margin has hovered around a slim 2.2%. In a high-interest-rate environment, this leaves no room for operational missteps. Despite beating revenue expectations in Q1 2026, adjusted EBITDA actually declined 9% year-over-year to $374.6 million.

8. Myriad Genetics, Inc. (NASDAQ:MYGN)

YTD Decline in Share Price: 18%

Glenview Capital’s Stake: $28 million 

Myriad Genetics, Inc. (NASDAQ:MYGN) has been a staple in the 13F portfolio of Glenview Capital since the third quarter of 2019. Back then, this position comprised 3.6 million shares. Since then, the fund has trimmed or increased this holding on a periodic basis. At one point in 2023, this position comprised close to 5.3 million shares. Filings for the fourth quarter of 2025 show that the fund owned almost 4.6 million shares in the firm, the same as in the previous quarter. Myriad is a molecular diagnostics and precision medicine company that develops molecular tests. It offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics.

Myriad Genetics, Inc. (NASDAQ:MYGN) has been unable to sway Wall Street despite years of restructuring. In Q1 2026, the firm reported a GAAP net loss of $34.1 million. Critics argue that if the company couldn’t find a path to profit during the height of the genetic testing boom, it is unlikely to do so now as competition intensifies. The bears also argue that the firm is losing share of wallet in the broader molecular diagnostics space. 12-month revenue growth of 5.7% significantly trails the US market average of 11.3%. Analysts at TD Cowen and Wells Fargo recently lowered their price targets on the stock following the Q1 miss.

READ ALSO: 15 Under-the-Radar Picks from David Einhorn That Are Quietly Dominating 2026.

7. DXC Technology Company (NYSE:DXC)

YTD Decline in Share Price: 19%

Glenview Capital’s Stake: $122 million 

DXC Technology Company (NYSE:DXC) has been a constant feature in the 13F portfolio of Glenview Capital since the second quarter of 2017. Back then, this position comprised just under 10 million shares. The fund has regularly made changes to this stake in the coming years but has not sold off the position completely at any time. Filings for the fourth quarter of 2025 show that the fund owned 8.3 million shares in the company, down slightly compared to filings for the previous quarter. DXC provides information technology services and solutions in the United States, the United Kingdom, the Rest of Europe, Australia, and internationally.

DXC Technology Company (NYSE:DXC) has been unable to find a floor for sales. The company reported Q4 2026 revenue of $3.13 billion, a 6.6% year-over-year decline. This marks the fourth consecutive quarter of revenue contraction. Analysts fear that the Global Infrastructure Services segment of the firm, the traditional plumbing of IT, is being permanently cannibalized by the shift to public cloud providers like AWS and Azure. Even with new AI initiatives, the new business is not yet large enough to offset the decay. DXC has pinned its future on DXC OASIS, an AI-driven managed services platform launched in April. However, there are question marks over ability to compete with AI-native firms or giants like Accenture and IBM, who have far deeper pockets.

6. IQVIA Holdings Inc. (NYSE:IQV)

YTD Decline in Share Price: 22%

Glenview Capital’s Stake: $45 million

IQVIA Holdings Inc. (NYSE:IQV) first appeared in the 13F portfolio of Glenview Capital in the fourth quarter of 2017. Back then, this position comprised 8.5 million shares. The fund started reducing this stake thereafter, steadily bringing it down to around 155,000 shares by the second quarter of 2021. It then sold off this holding completely. A new position in the stock was opened in the second quarter of 2025. This comprised 100,000 shares. Filings for the fourth quarter of 2025 show that the fund owned nearly 200,000 shares in the company, up close to 15% compared to filings for the third quarter of 2025.

Wall Street has been laser focused on the deceleration of organic growth for IQVIA Holdings Inc. (NYSE:IQV), with some analysts arguing that the company is struggling to maintain historical pace. Even though the $34.2 billion backlog is often cited as a strength, some experts view it as a potential liability if execution stalls. According to recent IQVIA Institute data, trial durations increased overall in late 2025 and early 2026, with inter-trial intervals rising by 3 months. Skeptics question the burn rate of this backlog. If trial durations continue to lengthen due to complex oncology requirements or regulatory hurdles, the conversion of that $34.2 billion into actual revenue will be pushed further into the future.

Click to continue reading and see 5 Stocks That Tanked: Why Larry Robbins’ Top Picks Are Struggling in 2026.

READ NEXT: 14 Best Defensive Stocks to Invest In Now and 14 Best Low Risk High Growth Stocks to Buy Right Now.

Disclosure: None. Follow Insider Monkey on Google News.